Oscar Health (NYSE:OSCR) Issues Quarterly Earnings Results, Beats Estimates By $0.63 EPS

Oscar Health (NYSE:OSCR) announced its earnings results on Thursday. The company reported $0.49 earnings per share for the quarter, beating the consensus estimate of ($0.14) by $0.63, FiscalAI reports. Oscar Health had a net margin of 3.60% and a return on equity of 38.45%. The firm had revenue of $5.14 billion during the quarter, compared to the consensus estimate of $4.69 billion. During the same quarter in the previous year, the company posted ($0.53) EPS. The firm’s revenue for the quarter was up 72.1% on a year-over-year basis.

Here are the key takeaways from Oscar Health’s conference call:

• Oscar raised its 2026 earnings-from-operations guidance for the third time, to $850 million–$950 million, citing favorable risk-adjustment results and utilization that was moderately better than expected. Through nine months, the company reported $1.2 billion in net income and $1.3 billion in earnings from operations.
• Third-quarter revenue rose 70% year over year to $5.1 billion, while the medical loss ratio improved to 84% and the SG&A expense ratio fell to a company-record 14%. Management attributed the efficiency gains to pricing discipline, fixed-cost leverage, expense controls, and technology and AI initiatives.
• Membership grew 27% year over year to 2.7 million, and Oscar is entering open enrollment across 713 counties, including a new South Carolina market. The company is also expanding products such as RetireEase and CHOICE, while its Lucie platform is projected to sell about 800,000 policies in 2027.
• For 2027, management expects overall ACA marketplace membership to be roughly stable year over year while aiming to gain share; its average rate increase is about 14%, reflecting high-single-digit medical-cost trend, higher market morbidity, and some margin expansion. New eligibility checks could create enrollment friction, though Oscar says it has prepared broker tools to help manage the process.
• Management cautioned that the $250 million third-quarter revenue benefit from updated risk-adjustment data does not all flow to earnings and is maintaining conservative reserves. Outpatient utilization was elevated, and Oscar expects a normal seasonal increase in fourth-quarter MLR.

Oscar Health Trading Down 7.3%

NYSE:OSCR traded down $2.44 during mid-day trading on Friday, reaching $30.74. The company’s stock had a trading volume of 8,874,950 shares, compared to its average volume of 4,643,670. The company’s fifty day simple moving average is $31.81 and its two-hundred day simple moving average is $23.97. The company has a debt-to-equity ratio of 0.21, a current ratio of 1.09 and a quick ratio of 1.09. Oscar Health has a twelve month low of $10.69 and a twelve month high of $38.50. The stock has a market cap of $9.49 billion, a P/E ratio of 12.70, a P/E/G ratio of 0.34 and a beta of 2.56.

Insider Buying and Selling

In other news, CAO Victoria Baltrus sold 958 shares of the stock in a transaction dated Thursday, September 3rd. The shares were sold at an average price of $31.45, for a total transaction of $30,129.10. Following the transaction, the chief accounting officer directly owned 213,631 shares in the company, valued at $6,718,694.95. This represents a 0.45% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director Mario Schlosser sold 31,422 shares of the stock in a transaction dated Thursday, September 3rd. The stock was sold at an average price of $31.45, for a total transaction of $988,221.90. Following the transaction, the director owned 449,444 shares in the company, valued at approximately $14,135,013.80. The trade was a 6.53% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold 874,451 shares of company stock worth $26,761,671 over the last ninety days. Insiders own 22.64% of the company’s stock.

Analysts Set New Price Targets

A number of research firms have recently weighed in on OSCR. Bank of America boosted their price objective on shares of Oscar Health from $28.00 to $30.00 and gave the company an “underperform” rating in a research report on Thursday, September 17th. Raymond James Financial upped their price objective on shares of Oscar Health from $34.00 to $42.00 and gave the company an “outperform” rating in a research note on Friday, September 18th. Robert W. Baird raised their target price on shares of Oscar Health from $27.00 to $33.00 and gave the stock a “neutral” rating in a research report on Thursday, September 17th. Wells Fargo & Company lifted their target price on shares of Oscar Health from $20.00 to $27.00 and gave the stock an “equal weight” rating in a research note on Thursday, August 13th. Finally, Weiss Ratings raised shares of Oscar Health from a “hold (c+)” rating to a “buy (b-)” rating in a research note on Thursday, October 8th. One research analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, seven have issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus price target of $34.60.

Key Oscar Health News

Here are the key news stories impacting Oscar Health this week:

• Positive Sentiment: Oscar reported Q3 adjusted earnings of $0.49 per share, versus analysts’ expected loss, and revenue of $5.14 billion, topping the $4.69 billion estimate and rising 72.1% year over year. Oscar Health beats Q3 earnings and revenue estimates
• Positive Sentiment: The company raised its 2026 revenue outlook to $19 billion–$19.3 billion, above the $18.64 billion FactSet estimate, and increased its full-year earnings outlook. Management cited improving medical costs and operating efficiencies as supporting margin gains, with expansion expected to contribute to 2027 growth. Q3 earnings call highlights outlook and margin gains
• Positive Sentiment: Operational indicators were also encouraging: membership increased 27.2% to 2.69 million, the medical loss ratio improved to 84.0%, and Oscar swung to a $167.3 million profit. Oscar Health Q3 revenue and membership growth
• Positive Sentiment: Zacks added OSCR to its Rank #1 (Strong Buy) growth-stocks list, reflecting favorable quantitative signals. Zacks growth stocks list
• Negative Sentiment: Piper Sandler lowered its price target from $48 to $45, although it maintained an Overweight rating. The new target still implies substantial upside from the referenced $30.74 share price. Piper Sandler rating information

About Oscar Health

Oscar Health, Inc is a technology-focused health insurance company that provides health plans and related services in the United States. The company primarily serves individuals and families purchasing coverage through the Affordable Care Act’s health insurance marketplace, as well as small businesses and their employees.

Oscar combines health insurance products with digital tools designed to help members manage their care. Its services include online enrollment, virtual care, provider search and appointment support, care navigation, claims and benefits information, and member engagement through web and mobile applications.